Custom immunoassays for ultrasensitive biomarker detection

Quanterix’s Homebrew Custom Assay Development is where innovation meets precision. Experience the flexibility, sensitivity, and simplicity of Simoa® technology, which enables the creation of custom assays that can be tailored to specific research requirements and biomarkers of interest.

Leveraging your antibodies and reagents and Quanterix’s Homebrew Custom Assay portfolio of products, users can quickly develop a personalized Simoa® immunoassay, allowing access to greater sensitivity, reproducibility, and more efficient workflows, especially when compared to traditional ELISA methods.

With Homebrew Custom Assays, a whole new wave of research ideas can be made into a reality, driving advancements in the fields of neurology, oncology, immunology, and beyond.

Quanterix’s Simoa® Homebrew Custom Assay Development solution has been designed to power laboratories worldwide.

Image Credit: Quanterix

• Accelerate assay development: Achieve rapid and high-performance bead and planar immunoassay development, reducing the time needed for assay optimization.
• Harness Simoa® technology: Gain access to ultrasensitive Simoa® technology, ensuring that assays deliver the gold standard in sensitivity and precision.
• Screen and test antibodies: Screen and test a wide range of antibodies, enabling the best candidate to be selected for your research.
• Unlock multiplexing possibilities: Explore multiplexing opportunities, which means multiple biomarkers can be analyzed simultaneously in your custom Simoa® assay.

No matter your requirements, Quanterix experts are a trusted partner when it comes to streamlining custom immunoassay development.

When the first batch reaches performance objectives, production can be scaled up to meet the research’s supply needs. This step ensures consistency and reliability in larger quantities.

The Simoa® Bead Homebrew Assay can be used with HD-1/HD-X and SR-X Systems. This innovative solution presents unparalleled surface chemistry. Bead-based immunoassays can also advance your research capabilities, starting with capturing and labeling analyte using the enzyme conjugate streptavidin ß‐galactosidase (SBG).

The analyte is captured with beads, and a biotinylated detection antibody is then added to create a captured analyte immunosandwich. The immunosandwich is labeled with SBG, with washing and incubation steps tailored to your personalized assay protocol.

A magnet pelletizes beads after every incubation. After a final wash cycle, the capture beads are resuspended in resorufin ß‐D‐galactopyranoside (RGP) substrate, ready for imaging and analyte quantification on a Simoa® disc.

The Simoa® Planar Array Homebrew Assay used with the SP-X Imaging and Analysis System™ provides universal assay plates with immobilized anchor antibodies in 96 microwells. These are very specific for use with the Simoa® planar arrays.

Everything required to perform peptide tag labeling for up to 6 capture antibodies and biotinylation for up to 6 detector antibodies is provided in the kit.

In the Simoa® planar assay format, the peptide-tagged capture antibody initially binds the plate-bound anchor. The assay then follows the familiar sandwich immunoassay format, with the antigen sandwiched between the peptide-tagged capture.

Biotinylated detector antibodies, streptavidin-HRP, and a chemiluminescent HRP substrate work together to signal the formation of immunocomplexes. The intensity of this signal directly correlates with the quantity of the analyte present in the standard or sample of interest.

Quanterix’s team of dedicated scientists is committed to maximizing the potential of custom assays. Quanterix offers comprehensive training and support:

Quanterix’s convenient on-site training provides the expertise for a seamless experience. Learn the principles of immunoassay optimization and validation alongside the specifics of Simoa® assay development. Receive guidance and insider tips and tricks to enhance the sensitivity of customized Simoa® assay. Collaborate with Quanterix experts on reagent preparations and customized prototype assay optimization. Discover multiplexing opportunities for developing a unique Simoa® assay.

Calibrate the assay to obtain optimal performance and sensitivity. If increased sensitivity is required, new batches can be generated and optimized to achieve the required performance levels.

Reagent batch scale-up:

Customized immunoassay development begins with preparing and evaluating an initial lot of capture beads and detector reagents to benchmark their sensitivity.

Assay optimization:

Reagent preparation and initial screening:

Image Credit: Quanterix

Flexible

Researchers can customize their study of any analyte by utilizing their own antibodies and personalized assay protocols with our Homebrew kits. These kits are compatible with the HD-1, HD-X, SR-X, or SP-X instruments they may already possess.

Ultrasensitive

Quanterix’s Accelerator Laboratory provides the necessary support for those without access to instruments. Compared to conventional ELISAs, the ultrasensitive power of Simoa® technology considerably improves sensitivity.

Multiplex

Multiplex can measure multiple targets simultaneously with customized Homebrew assays on the Quanterix bead platform, detecting up to four analytes from a single sample.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. Quanterix’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods.

Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,500 peer-reviewed journals.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.